With its vaccine schedule, “Denmark has made a values choice to accept preventable hospitalizations and illnesses that other ...

Nine drugmakers are set to unveil deals with the Trump administration to lower the prices of some of their drugs, marking the ...

It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...

WASHINGTON — Brand drugmakers have agreed to donate bulk ingredients to a national stockpile as part of deals with the Trump ...

A vaccine adviser at the CDC with ties to health secretary Robert F. Kennedy Jr. is being given a new portfolio overseeing ...

UnitedHealth Group said Friday that the consultants it hired to audit its operations found they’re not only “robust,” but ...

Two government officials told STAT that the White House has been involved in final decisions about the FDA's new priority ...

BioMarin's new CEO had promised Wall Street there would be deals, and with Amicus, it has one the market likes.

The Trump administration has announced sweeping policies that, if enacted, could effectively end gender-affirming care for ...

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

The U.K. government wants to boost the local life sciences industry, and it hopes to entice American venture capital firms to ...